Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.84 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GPR6 | P46095 | 6/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.30 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13413197 | 0.97 | CTSB (0.89) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL13248866 | 0.97 | CTSB (0.89) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL8285124 | 0.91 | CTSB (1.00) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL13385475 | 0.90 | CTSB (0.88) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL13248865 | 0.88 | CTSB (0.82) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3052431 | 0.88 | CTSB (0.82) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL8286038 | 0.88 | CTSB (0.83) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL8284369 | 0.87 | CTSB (0.72) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL8248104 | 0.82 | CTSB (0.82) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL15641017 | 0.81 | CTSB (0.69) | CTSBCTSSADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2007-08-30 | — | — | US | disclosed |
| EP-1713823-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073195-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203072-A1 | Hcv Ns-3 Serine Protease Inhibitors | HPN, CPN1, PRSS1 | CTSB 126/4885CTSS 69/4885ADRB3 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.